Epstein Secrets

. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing

Act litigation blasted the government's reasoning to leave Epstein's non-prosecution agreement in place. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing to prosecute Epstein because of privacy concerns can simply decline to do so and remain anonymous.

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing

Act litigation blasted the government's reasoning to leave Epstein's non-prosecution agreement in place. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing to prosecute Epstein because of privacy concerns can simply decline to do so and remain anonymous.

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing

Act litigation blasted the government's reasoning to leave Epstein's non-prosecution agreement in place. Lawyers Bradley Edwards, Paul Cassell and Jack Scarola say any South Florida victims who are not willing to prosecute Epstein because of privacy concerns can simply decline to do so and remain anonymous.

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been